» Articles » PMID: 8560311

Maximizing Health Benefits Vs Egalitarianism: an Australian Survey of Health Issues

Overview
Journal Soc Sci Med
Date 1995 Nov 1
PMID 8560311
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

Economists have often treated the objective of health services as being the maximization of the QALYs gained, irrespective of how the gains are distributed. In a cross section of Australians such a policy of distributive neutrality received: (a) very little support when health benefits to young people compete with health benefits to the elderly; (b) only moderate support when those who can become a little better compete with those who can become much better; (c) only moderate support when smokers compete with non smokers; (d) some support when young children compete with newborns; and (e) wide spread support when parents of dependent children compete with people without children. Overall, the views of the study population were strongly egalitarian. A policy of health benefit maximization received very limited support when the consequence is a loss of equity and access to services for the elderly and for people with a limited potential for improving their health.

Citing Articles

Rationale, conceptual issues, and resultant protocol for a mixed methods Person Trade Off (PTO) and qualitative study to estimate and understand the relative value of gains in health for children and young people compared to adults.

Peasgood T, Bailey C, Chen G, De Silva A, De Silva Perera U, Norman R PLoS One. 2024; 19(6):e0302886.

PMID: 38829857 PMC: 11146702. DOI: 10.1371/journal.pone.0302886.


A principled approach to non-discrimination in cost-effectiveness.

Lakdawalla D, Doctor J Eur J Health Econ. 2024; 25(8):1393-1416.

PMID: 38411845 PMC: 11639167. DOI: 10.1007/s10198-023-01659-7.


Applying ethical theories to the Iranian health system governance: a critical empirical assessment.

Bahmanziari N, Mohammadi S, Takian A, Arab M, Harirchi I J Med Ethics Hist Med. 2022; 14:23.

PMID: 35600216 PMC: 9076495. DOI: 10.18502/jmehm.v14i23.8183.


A guide to extending and implementing generalized risk-adjusted cost-effectiveness (GRACE).

Lakdawalla D, Phelps C Eur J Health Econ. 2021; 23(3):433-451.

PMID: 34495445 PMC: 8964662. DOI: 10.1007/s10198-021-01367-0.


Value-based drug pricing in the Biden era: Opportunities and prospects.

Neumann P, Ollendorf D, Cohen J Health Serv Res. 2021; 56(6):1093-1099.

PMID: 34085289 PMC: 8586482. DOI: 10.1111/1475-6773.13686.